Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun 26;11(7):1169.
doi: 10.3390/diagnostics11071169.

Cytogenetic and Biochemical Genetic Techniques for Personalized Drug Therapy in Europe

Tatjana Huebner  1 , Catharina Scholl  1 , Michael Steffens  1
Affiliations
Review

Cytogenetic and Biochemical Genetic Techniques for Personalized Drug Therapy in Europe

Tatjana Huebner et al. Diagnostics (Basel). .

Abstract

For many authorized drugs, accumulating scientific evidence supports testing for predictive biomarkers to apply personalized therapy and support preventive measures regarding adverse drug reactions and treatment failure. Here, we review cytogenetic and biochemical genetic testing methods that are available to guide therapy with drugs centrally approved in the European Union (EU). We identified several methods and combinations of techniques registered in the Genetic Testing Registry (GTR), which can be used to guide therapy with drugs for which pharmacogenomic-related information is provided in the European public assessment reports. Although this registry provides information on genetic tests offered worldwide, we identified limitations regarding standard techniques applied in clinical practice and the information on test validity rarely provided in the according sections.

Keywords: companion diagnostic; in vitro diagnostic; personalized therapy; pharmacogenetics; pharmacogenomics; regulation.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Guideline on the Use of Pharmacogenetic Methodologies in the Pharmacokinetic Evaluation of Medicinal Products. [(accessed on 10 June 2020)]; Available online: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-us....
    1. Ehmann F., Caneva L., Prasad K., Paulmichl M., Maliepaard M., Llerena A., Ingelman-Sundberg M., Papaluca-Amati M. Pharmacogenomic information in drug labels: European Medicines Agency perspective. Pharm. J. 2015;15:201–210. doi: 10.1038/tpj.2014.86. - DOI - PubMed
    1. Concept Paper on Predictive Biomarker-Based Assay Development in the Context of Drug Development and Lifecycle. [(accessed on 7 October 2020)]; Available online: https://www.ema.europa.eu/en/documents/scientific-guideline/concept-pape....
    1. European Medicines Agency Reflection Paper on Pharmacogenomics in Oncology. [(accessed on 7 October 2020)];Comm. Hum. Med. Prod. 2008 Available online: https://www.google.com.hk/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2a....
    1. REGULATION (EU) 2017/746 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL. [(accessed on 4 March 2021)]; Available online: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32017R0746.

LinkOut - more resources